The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InProtagonist Therapeutics reported a significant earnings beat, posting a surprise profit of $0.05 per share against an expected loss of $0.65. This performance, driven by revenue of $56.37 million, led Citizens Jmp to set a new price target of $137.00 for the stock. However, market caution persists as insider sales have exceeded $15 million over the past 90 days. Despite these sales, institutional confidence remains exceptionally high, with institutional ownership reaching 98.63%. Investors are now focused on whether the company can maintain this momentum and achieve sustained profitability. This combination of strong earnings and high institutional backing marks a pivotal phase for the biotechnology firm's market valuation.